The Wall Street Journal ad creative
The Wall Street Journal
The Wall Street Journal

Inactive· since Apr 1, 2026

36
days it ran
0
relaunches

Ad copy

We’ve all heard that stopping taking a GLP-1 medication for weight loss—such as semaglutide (marketed as Wegovy) and tirzepatide (sold as Zepbound)—often leads to rapid weight gain, with people returning to baseline in as little as 18 months. What you might not have heard: For some people, the return of hunger and thoughts of food come back leading to potential weight gain—even while they are still taking the drug, which mimics naturally occurring gut hormones, suppressing appetite and making people feel full faster. 🔗 Read more: https://www.wsj.com/health/wellness/when-miracle-weight-loss-drugs-lose-their-edge-93d8b8fd

🪄Crush AI

Like this ad? Make it yours.

Crush rebuilds this exact creative around your product — your brand, your colors, your offer — in about a minute.

More ads from The Wall Street Journal

The Wall Street JournalThe Wall Street Journal
Active
74 Days
-Reach
1Ads
The Wall Street Journal Facebook ad
Details
The Wall Street JournalThe Wall Street Journal
Active
74 Days
-Reach
1Ads
The Wall Street Journal Facebook ad
Details
The Wall Street JournalThe Wall Street Journal
Active
6 Days
-Reach
1Ads
The Wall Street Journal Facebook ad
Details
The Wall Street JournalThe Wall Street Journal
Active
6 Days
-Reach
1Ads
The Wall Street Journal Facebook ad
Details
The Wall Street JournalThe Wall Street Journal
Inactive
8 Days
-Reach
1Ads
The Wall Street Journal Facebook ad
Details
The Wall Street JournalThe Wall Street Journal
Inactive
8 Days
-Reach
1Ads
The Wall Street Journal Facebook ad
Details
The Wall Street JournalThe Wall Street Journal
Inactive
8 Days
-Reach
1Ads
The Wall Street Journal Facebook ad
Details
The Wall Street JournalThe Wall Street Journal
Inactive
34 Days
-Reach
1Ads
The Wall Street Journal Facebook ad
Details
The Wall Street Journal Ad — Ran 36 Days | Crush Ad Library